Exozymes Inc. announced on June 24, 2026, that it received a $2 million grant from the National Institutes of Health (NIH). The funding is intended to support the advancement of cannabinoid analogs for drug discovery purposes. Exozymes Inc. is a biotechnology company focused on drug discovery.

eXoZymes Inc. completed a firm commitment underwritten offering of 592,270 units at $18.00 per unit, with each unit consisting of two shares of common stock and one warrant. On June 17, 2026, the underwriter MDB Capital exercised an over-allotment option to purchase 34,440 additional units. Including the over-allotment, the company generated approximately $5.95 million in gross proceeds. Net proceeds are intended to fund N-trans-caffeoyltyramine (NCT) development, research and development, and general working capital. eXoZymes Inc. is a biotechnology company focused on product development and commercialization.

eXoZymes Inc. entered into an Underwriting Agreement with MDB Capital on June 5, 2026, to conduct a firm commitment underwritten offering of 592,270 shares of common stock and 292,135 warrants. The offering price per unit was $18.00, with expected gross proceeds of approximately $5,330,430.